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In this issue of Current Controlled Trials in Cardiovascular
Medicine, Ray et al [1] report the results of a study on
genetic and acquired risk factors for venous thrombosis in
women. This paper is remarkable, not only because it
focuses on women, but also because it is an observa-
tional, case–control study rather than a randomized trial.
In their editorial in the first issue of the journal, editors-in-
chief Curt Furberg and Bertram Pitt did not explicitly
mention randomized trials – they spoke of a journal for
‘clinical trials’ [2]. This suggests experimental rather than
observational studies, but does not necessarily imply ran-
domization. Nevertheless, by encouraging prospective
authors to report trial results according to the Consoli-
dated Standards of Reporting Trials guidelines [3], they
implicitly made it clear that the journal was aimed at
reporting randomized clinical trials.
Does this publication therefore represent a major change in
policy? Did it take only a handful of issues before the editors
decided to ‘lower’ their standards? I think not. Sir Austin
Bradford Hill is credited with performing the first properly
randomized trial in 1948 [4], although studies with some
form of random treatment allocation antedated it by at least
50 years [5]. When we read his Principles of Medical
Statistics, from the first edition in 1937 [6] to the last post-
humous edition of 1984 [7], we see an increasing emphasis
on randomization, the use of placebo controls and double
blinding. However, even as a strong advocate for experi-
mentation, he defined a clinical trial as a study in which we
learn from a patient; up to the 12th edition he continued to
quote the 1949 Presidential Address to the Royal Society
of Medicine by Sir George Pickering, who argued that all
that happened to a patient should be recorded.
Randomization is a tool, not a goal in and of itself. The
goal of clinical research is to obtain an answer that is
valid and precise, and the ultimate goal is to prevent and
treat disease in the best way. Each study design has indi-
cations and contraindications. The main threats to validity
in treatment studies are regression to the mean (ie
improvement due to the natural course of a disorder) and
‘confounding by indication’ (ie incomparability of groups
when the risk profile affects the choice of drug). Control
groups are included to address regression to the mean,
whereas randomization is aimed at creating groups with
similar prognosis to combat confounding by indication. In
clinical practice, physicians tailor treatment to a patient’s
prognosis, and so a simple comparison of patients treated
with different regimens will often be biased. Because of
the need to counter this confounding by indication, ran-
domization has become nearly synonymous with good
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research into medical therapies. Many have broadened
this to the belief that randomization is synonymous with
good research, and have created a hierarchy of study
designs. This is a mistake. First, randomized trials do have
drawbacks. Secondly, they are not always possible, or, for
that matter, ethical.
One important drawback of randomized trials is that they
typically involve patients who were considered fit to enter,
were likely to finish the trial, and believed, or even shown
during a run-in phase, to comply with the medications.
This population is quite different from the patients in the
waiting room. Another important drawback is that,
because the precision of an estimate is dependent on the
number of patients experiencing an event, randomized
trials, unless they are very large, will seldom be precise. A
third drawback is that in all prospective studies, including
randomized trials, it is seldom possible to relate the
outcome of interest to determinants that occurred immedi-
ately before that outcome, and that might even have inter-
acted in producing it (for instance lifestyle factors,
intercurrent disease). In some cases, randomization is
simply not possible, as in aetiological studies of genetic
variants. Also, even for nongenetic risk factors, randomiza-
tion would often lead to ethical problems (for instance,
studies on the effects of alcohol).
Case–control studies, such as the one on venous throm-
bosis published in the present issue [1], have other indica-
tions and contraindications. In this type of study, patients
with the outcome of interest are contrasted to those
without, and therefore the precision of the estimate is
much greater. Ideally, all patients in a certain geographical
region are included, so generalizibility is better. Finally, in
contrast to randomized trials and other cohort studies,
patients can be seen shortly after the event and recent risk
factors can be recorded.
Case–control studies also have drawbacks; if the disease
changes the risk factor measurement, then inference
becomes difficult (for instance, varicose veins are often
seen after a deep vein thrombosis, but are probably not a
cause of venous thrombosis). In studies of treatments,
case–control studies, like all observational studies, may be
subject to bias through confounding by indication. It is
important to make a distinction between expected or
intended effects (efficacy), and unintended or unexpected
effects (side effects). Although in the case of efficacy con-
founding by indication is a likely source of bias, this is not
so in the case of side effects. If physicians or patients
neither intend nor expect a certain effect of a drug, then
the presence of risk factors for that effect is unlikely to
affect prescription, and therefore groups using and not
using the drug will be comparable, and estimates will be
unbiased. This can be illustrated with the effects of
hormone replacement therapy. A large observational study
(the Nurses’ Health study) showed a strong protective
effect on coronary heart disease [8] that was not con-
firmed in a randomized trial [9]. Both studies found very
similar relative risks of venous thrombosis, which was an
unexpected side effect [10,11].
Genetic studies on the aetiology of disease and side
effects of drugs are needed to direct or complement ran-
domized trials of therapies. For both such study types the
case–control design is the best choice. It is therefore
appropriate that case–control studies and randomized
controlled trials are published side by side, in order to
serve our ultimate goal of improving patient care.
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